僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Talacotuzumab （JNJ 56022473; CSL 362） is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 （FcγRIIIa）, thereby enhancing antibody-dependent cell-mediated cytotoxicity （ADCC）.